Selamectin Topical Solution

Firmly press the cap down to puncture the seal on the Selamectin tube; a clicking sound will confirm that the cap has successfully punctured the seal. Remove the cap and check to ensure that the tip of the tube is open. To administer the product, part the hair on the back of the animal at the base of the neck in front of the shoulder blades until the skin is visible. Place the tip of the tube on the skin and squeeze the tube 3 or 4 times to empty its entire contents directly onto the skin in one spot. Keeping the tube squeezed, drag it away from the liquid and lift to remove. Check the tube to ensure that it is empty. Do not massage the product into the skin. Due to alcohol content, do not apply to broken skin. Avoid contact between the product and fingers. Do not apply when the haircoat is wet. Bathing or shampooing the dog 2 or more hours after treatment will not reduce the effectiveness of Selamectin against fleas or heartworm. Bathing or shampooing the cat 2 hours after treatment will not reduce the effectiveness of Selamectin against fleas. Bathing or shampooing the cat 24 hours after treatment will not reduce the effectiveness of Selamectin against heartworm. Stiff hair, clumping of hair, hair discoloration, or a slight powdery residue may be observed at the treatment site in some animals. These effects are temporary and do not affect the safety or effectiveness of the product. Discard empty tubes in your ordinary household refuse.

Flea Control In Dogs And Cats

For the prevention and control of flea infestations, Selamectin should be administered at monthly intervals throughout the flea season, starting one month before fleas become active. In controlled laboratory studies >98% of fleas were killed within 36 hours. Results of clinical field studies using selamectin monthly demonstrated >90% control of flea infestations within 30 days of the first dose. Dogs and cats treated with selamectin, including those with pre-existing flea allergy dermatitis, showed improvement in clinical signs associated with fleas as a direct result of eliminating the fleas from the animals and their environment.

If the dog or cat is already infested with fleas when the first dose of Selamectin is administered, adult fleas on the animal are killed and no viable fleas hatch from eggs after the first administration. However, an environmental infestation of fleas may persist for a short time after beginning treatment with Selamectin because of the emergence of adult fleas from pupae.

Heartworm Prevention In Dogs And Cats

For the prevention of heartworm disease, Selamectin must be administered on a monthly basis. Selamectin may be administered year-round or at least within one month after the animal’s first exposure to mosquitoes and monthly thereafter until the end of the mosquito season. The final dose must be given within one month after the last exposure to mosquitoes. If a dose is missed and a monthly interval between dosing is exceeded then immediate administration of Selamectin and resumption of monthly dosing will minimize the opportunity for the development of adult heartworms. When replacing another heartworm preventive product in a heartworm disease prevention program, the first dose of Selamectin must be given within a month of the last dose of the former medication.

Selamectin, the active ingredient in Selamectin, is a macrocyclic lactone compound. These compounds effectively prevent the development of adult heartworms when administered to dogs and cats within one month of exposure to infective (L₃) Dirofilaria immitis larvae. Efficacy of macrocyclic lactones decreases below 100% in dogs, however, if first administered >2 months after exposure to infective larvae. Thus, in heartworm endemic regions, delaying initiation of heartworm prevention using Selamectin beyond 2 months of first exposure to infective larvae (e.g., starting puppies and kittens at >8 weeks of age), or gaps of >2 months in the administration of Selamectin during periods of heartworm transmission, increases the risk of the animal acquiring heartworms. Animals with unknown heartworm history that test negative for heartworms prior to the initiation of Selamectin may be harboring pre-patent infections at the time Selamectin was started. Testing such animals 3-4 months after initiation of Selamectin would be necessary to confirm their negative heartworm status.

At the discretion of the veterinarian, cats ≥6 months of age may be tested to determine the presence of existing heartworm infections before beginning treatment with Selamectin. Cats already infected with adult heartworms can be given Selamectin monthly to prevent further infections.

Ear Mite Treatment In Dogs And Cats

For the treatment of ear mite (O. cynotis) infestations in dogs and cats, Selamectin should be administered once as a single topical dose. A second monthly dose may be required in some dogs. Monthly use of Selamectin will control any subsequent ear mite infestations. In the clinical field trials ears were not cleaned, and many animals still had debris in their ears after the second dose. Cleansing of the infested ears is recommended to remove the debris.

Sarcoptic Mange Treatment In Dogs

For the treatment of sarcoptic mange (S. scabiei) in dogs, Selamectin should be administered once as a single topical dose. A second monthly dose may be required in some dogs. Monthly use of Selamectin will control any subsequent sarcoptic mange mite infestations. Because of the difficulty in finding sarcoptic mange mites on skin scrapings, effectiveness assessments also were based on resolution of clinical signs. Resolution of the pruritus associated with the mite infestations was observed in approximately 50% of the dogs 30 days after the first treatment and in approximately 90% of the dogs 30 days after the second monthly treatment.

Tick Control In Dogs

For the control of tick (Dermacentor variabilis) infestations in dogs, Selamectin should be administered on a monthly basis. In heavy tick infestations, complete efficacy may not be achieved after the first dose. In these cases, one additional dose may be administered two weeks after the previous dose, with monthly dosing continued thereafter.

Nematode Treatment In Cats

For the treatment and control of intestinal hookworm (A. tubaeforme) and roundworm (T. cati) infections, Selamectin should be applied once as a single topical dose.

Warnings

User Safety Warnings

Not for human use. Keep out of reach of children.

In humans, Selamectin may be irritating to skin and eyes.

Reactions such as hives, itching and skin redness have been reported in humans. Individuals with known hypersensitivity to Selamectin should use the product with caution or consult a health care professional. Selamectin contains isopropyl alcohol and the preservative butylated hydroxytoluene (BHT).

Wash hands after use and wash off any product in contact with the skin immediately with soap and water.

If contact with eyes occurs, then flush eyes copiously with water; if wearing contact lenses, rinse the eyes first then remove contact lenses and continue to rinse for 5-10 minutes and seek medical attention.

In case of ingestion by a human, contact a physician immediately.

The safety data sheet (SDS) provides more detailed occupational safety information.

To obtain a SDS contact ZyVet Animal Health Inc. at 1-877-779-9838.

Flammable - Keep away from heat, sparks, open flames or other sources of ignition.

Animal Safety Warnings

Do not use in sick, debilitated or underweight animals (see TARGET ANIMAL SAFETY).

Precautions

Prior to administration of Selamectin, dogs should be tested for existing heartworm infections. At the discretion of the veterinarian, infected dogs should be treated to remove adult heartworms. Selamectin is not effective against adult D. immitis and, while the number of circulating microfilariae may decrease following treatment, Selamectin is not effective for microfilariae clearance.

Hypersensitivity reactions have not been observed in dogs with patent heartworm infections administered Selamectin (see TARGET ANIMAL SAFETY).

Adverse Reactions

Pre-Approval Clinical Trials:

Following treatment with Selamectin, transient localized alopecia with or without inflammation at or near the site of application was observed in approximately 1% of 691 treated cats. Other signs observed (≤0.5% of 1743 treated cats and dogs) included vomiting, loose stool or diarrhea with or without blood, anorexia, lethargy, salivation, tachypnea, and muscle tremors.

Post-Approval Experience (2021):

The following adverse events are based on post-approval adverse drug experience reporting for selamectin. Not all adverse events are reported to FDA/CVM. It is not always possible to reliably estimate the adverse event frequency or establish a causal relationship to product exposure using this data.

The following adverse events reported for dogs are listed in decreasing order of reporting frequency:

Lethargy, vomiting, diarrhea, anorexia, generalized pruritus, seizures, application site reactions (including alopecia, lesions, erythema, pruritis, and inflammation), tremors, ataxia, death, and dermatitis.

The following adverse events reported for cats are listed in decreasing order of reporting frequency:

Application site reactions (including alopecia, lesions, erythema, pruritus, inflammation, vesicles, blisters, and excoriations), lethargy, anorexia, vomiting, death, generalized pruritus, diarrhea, ataxia, fever, generalized alopecia, tremors, hypersalivation, dermatitis, and seizures.

CONTACT INFORMATION:

To report suspected adverse drug events, for technical assistance or to obtain a copy of the Safety Data Sheet (SDS), contact ZyVet Animal Health Inc. at 1-877-779-9838. For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS or http://www.fda.gov/reportanimalae

TARGET ANIMAL SAFETY:

Selamectin has been tested safe in over 100 different pure and mixed breeds of healthy dogs and over 15 different pure and mixed breeds of healthy cats, including pregnant and lactating females, breeding males and females, puppies six weeks of age and older, kittens eight weeks of age and older, and avermectin-sensitive collies. A kitten, estimated to be 5-6 weeks old (0.3 kg), died 8 1⁄2 hours after receiving a single treatment of selamectin at the recommended dosage. The kitten displayed clinical signs which included muscle spasms, salivation and neurological signs. The kitten was a stray with an unknown history and was malnourished and underweight (see WARNINGS).

DOGS: In safety studies, selamectin was administered at 1, 3, 5, and 10 times the recommended dose to six-week-old puppies, and no adverse reactions were observed. The safety of selamectin administered orally also was tested in case of accidental oral ingestion. Oral administration of selamectin at the recommended topical dose in 5- to 8- month-old beagles did not cause any adverse reactions. In a pre-clinical study selamectin was dosed orally to ivermectin-sensitive collies. Oral administration of 2.5, 10, and 15 mg/kg in this dose escalating study did not cause any adverse reactions; however, eight hours after receiving 5 mg/kg orally, one avermectin-sensitive collie became ataxic for several hours, but did not show any other adverse reactions after receiving subsequent doses of 10 and 15 mg/kg orally. In a topical safety study conducted with avermectin-sensitive collies at 1, 3 and 5 times the recommended dose of selamectin, salivation was observed in all treatment groups, including the vehicle control. Selamectin also was administered at 3 times the recommended dose to heartworm infected dogs, and no adverse effects were observed.

CATS: In safety studies, selamectin was applied at 1, 3, 5, and 10 times the recommended dose to six-week-old kittens. No adverse reactions were observed. The safety of selamectin administered orally also was tested in case of accidental oral ingestion. Oral administration of the recommended topical dose of selamectin to cats caused salivation and intermittent vomiting. Selamectin also was applied at 4 times the recommended dose to patent heartworm infected cats, and no adverse reactions were observed.

In well-controlled clinical studies, selamectin was used safely in animals receiving other frequently used veterinary products such as vaccines, anthelmintics, antiparasitics, antibiotics, steroids, collars, shampoos and dips.

STORAGE CONDITIONS: Store below 30°C (86°F).

How Supplied

Available in three separate dose strengths for dogs and cats of different weights (see DOSAGE). Selamectin for puppies and kittens is available in cartons containing 3 single dose tubes. Selamectin for cats is available in cartons containing 3 or 6 single dose tubes.

Approved by FDA under ANADA # 200-769

Manufactured by:

Zydus Animal Health and Investments Limited, Ahmedabad, India

Distributed by:

ZyVet Animal Health Inc., Pennington, NJ 08534

Rev.: 12/23

CPN: 2132005.0